Top 5 Drug Type | Count |
---|---|
Monoclonal antibody | 7 |
Small molecule drug | 7 |
Enzyme | 1 |
siRNA | 1 |
Recombinant coagulation factor | 1 |
Target |
Mechanism AT III inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date28 Mar 2025 |
Target |
Mechanism F10 stimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date22 Feb 2023 |
Target |
Mechanism CD3 inhibitors |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date17 Nov 2022 |
Start Date05 Nov 2024 |
Sponsor / Collaborator |
Start Date21 Oct 2024 |
Sponsor / Collaborator |
Start Date11 Oct 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Avalglucosidase alfa ( M6PR x α-glucosidase ) | Glycogen Storage Disease Type II More | Approved |
Dupilumab ( IL-4Rα ) | Pulmonary Disease, Chronic Obstructive More | Approved |
Isatuximab-IRFC | Multiple Myeloma More | Approved |
Metildigoxin | Heart Failure More | Approved |
Teplizumab ( CD3 ) | Diabetes Mellitus, Type 1 More | NDA/BLA |